142 related articles for article (PubMed ID: 1470911)
21. Live-attenuated HIV vaccines: how safe is safe enough?
Murphey-Corb M
Nat Med; 1997 Jan; 3(1):17-8. PubMed ID: 8986728
[No Abstract] [Full Text] [Related]
22. CTL ontogeny and viral escape: implications for HIV-1 vaccine design.
Yang OO
Trends Immunol; 2004 Mar; 25(3):138-42. PubMed ID: 15036041
[No Abstract] [Full Text] [Related]
23. Vaccination against SIV infection and disease.
Gardner MB
AIDS Res Hum Retroviruses; 1990 Jul; 6(7):835-46. PubMed ID: 2167709
[No Abstract] [Full Text] [Related]
24. Safety issues facing development of a live-attenuated, multiply deleted HIV-1 vaccine.
Desrosiers RC
AIDS Res Hum Retroviruses; 1994 Apr; 10(4):331-2. PubMed ID: 8068412
[No Abstract] [Full Text] [Related]
25. Reconsidering an attenuated vaccine for AIDS.
Beale J
Lancet; 1996 Feb; 347(8998):344-5. PubMed ID: 8598696
[No Abstract] [Full Text] [Related]
26. HIV vaccine design: insights from live attenuated SIV vaccines.
Koff WC; Johnson PR; Watkins DI; Burton DR; Lifson JD; Hasenkrug KJ; McDermott AB; Schultz A; Zamb TJ; Boyle R; Desrosiers RC
Nat Immunol; 2006 Jan; 7(1):19-23. PubMed ID: 16357854
[TBL] [Abstract][Full Text] [Related]
27. An attenuated vaccine for AIDS?
Beale J
Lancet; 1995 May; 345(8961):1318-9. PubMed ID: 7752750
[TBL] [Abstract][Full Text] [Related]
28. The biochemistry of AIDS.
Vaishnav YN; Wong-Staal F
Annu Rev Biochem; 1991; 60():577-630. PubMed ID: 1883204
[No Abstract] [Full Text] [Related]
29. Live HIV vaccines--how safe?
Dittmer U; Stahl-Hennig C; Hunsmann G
Nat Med; 1997 Aug; 3(8):816. PubMed ID: 9256262
[No Abstract] [Full Text] [Related]
30. AIDS doctors push for live-virus vaccine trials.
McCarthy M
Lancet; 1997 Oct; 350(9084):1082. PubMed ID: 10213561
[No Abstract] [Full Text] [Related]
31. Attenuated retrovirus vaccines and AIDS.
Shearer GM; Lucey DR; Clerici M
Science; 1995 Nov; 270(5239):1219; author reply 1220-2. PubMed ID: 7502053
[No Abstract] [Full Text] [Related]
32. HIV/AIDS: vaccines and alternate strategies for treatment and prevention.
Voronin Y; Phogat S
Ann N Y Acad Sci; 2010 Sep; 1205 Suppl 1():E1-9. PubMed ID: 20860672
[TBL] [Abstract][Full Text] [Related]
33. [Brief history of AIDS in non-human primates and its contribution to the study of acquired immunodeficiency syndrome].
Málaga CA; Kraiselburd E; Lavergne JA; Del Llano AM; Amieiro JP
P R Health Sci J; 1993 Apr; 12(1):47-54. PubMed ID: 8511246
[TBL] [Abstract][Full Text] [Related]
34. Vaccine studies with the 32H reisolate of SIVmac251: an overview.
Cranage M; Stott J; Mills K; Ashworth T; Taffs F; Farrar G; Chan L; Dennis M; Putkonen P; Biberfeld G
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1479-81. PubMed ID: 1466987
[No Abstract] [Full Text] [Related]
35. Attenuated vaccines for AIDS.
Victorino RM; Sousa AE
Lancet; 1995 Jul; 346(8968):179. PubMed ID: 7603240
[No Abstract] [Full Text] [Related]
36. AIDS vaccine development in primate models.
Almond NM; Heeney JL
AIDS; 1998; 12 Suppl A():S133-40. PubMed ID: 9632994
[No Abstract] [Full Text] [Related]
37. Aids vaccine advance.
Novak K; MacFarlane J; Aamodt S
Nat Med; 2000 Nov; 6(11):1220. PubMed ID: 11062531
[No Abstract] [Full Text] [Related]
38. A noninfectious simian/human immunodeficiency virus DNA vaccine that protects macaques against AIDS.
Singh DK; Liu Z; Sheffer D; Mackay GA; Smith M; Dhillon S; Hegde R; Jia F; Adany I; Narayan O
J Virol; 2005 Mar; 79(6):3419-28. PubMed ID: 15731236
[TBL] [Abstract][Full Text] [Related]
39. New gene-based approaches for an AIDS vaccine.
Puaux AL; Michel ML
Comp Immunol Microbiol Infect Dis; 2003 Oct; 26(5-6):357-72. PubMed ID: 12818622
[TBL] [Abstract][Full Text] [Related]
40. Cytotoxic T lymphocytes in AIDS pathogenesis: lessons to be learned from the macaque model of simian immunodeficiency virus infection.
Geretti AM; Hulskotte E; Osterhaus AD
J Gen Virol; 1998 Mar; 79 ( Pt 3)():415-21. PubMed ID: 9519818
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
